Trial · NCT06284122
Registered outcomes37
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 37
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression Free Survival (PFS) | 130 PFS events assessed by an Independent Review Committee (IRC) (4.6 years) | time from randomization to the date of first documented disease progression/relapse or death from any cause, by Lugano 2014 |
| Primary | Progression Free Survival (PFS) | 173 PFS events assessed by IRC (5.8 y) | time from randomization to the date of first documented disease progression/relapse or death from any cause, by Lugano 2014 |
| Secondary | Overall Response (OR) | 6 months | by Lugano 2014 (PET-CT based response), assessed by investigator and IRC |
| Secondary | Complete Metabolic Rate (CMR) | 6 months | by Lugano 2014 (PET-CT based response), assessed by investigator and IRC |
| Secondary | Overall Response (OR) | 12 months | by Lugano 2014 (PET-CT based response), assessed by investigator and IRC |
| Secondary | Complete Metabolic Rate (CMR) | 12 months | by Lugano 2014 (PET-CT based response), assessed by investigator and IRC |
| Secondary | Overall Response (OR) and Complete Response (CR) rate at EOT | 4.6 years | by Lugano 2014 (PET-CT based response), assessed by investigator and IRC |
| Secondary | Best Overall Response (CR or PR) rate | 5.8 years | by Lugano 2014 (PET-CT based response), assessed by investigator and IRC |
| Secondary | Progression of disease within 2 years (POD24) | 2 years | rate of progression of disease (POD) within 2 years of first line therapy |
| Secondary | PFS | 4.6 years | by Lugano 2014, assessed by investigator |
| Secondary | PFS | 5.8 years | by Lugano 2014, assessed by investigator |
| Secondary | Event Free Survival (EFS) by Lugano 2014 | 4.6 years | time between randomization and date of first documented disease progression/relapse, initiation of a new anti-lymphoma treatment or death from any cause |
| Secondary | Event Free Survival (EFS) by Lugano 2014 | 5.8 years | time between randomization and date of first documented disease progression/relapse, initiation of a new anti-lymphoma treatment or death from any cause |
| Secondary | Time to Next Anti-Lymphoma Treatment (TTNLT) | 4.6 years | time between randomization and date of first documented administration of any new anti-lymphoma treatment |
| Secondary | Time to Next Anti-Lymphoma Treatment (TTNLT) | 5.8 years | time between randomization and date of first documented administration of any new anti-lymphoma treatment |
| Secondary | Duration of response | 4.6 years | defined for patients with a best overall response of CR or PR determined by Lugano 2014 (PET-CT based response), defined as the time of 1st occurrence of CR or PR to disease progression/relapse or death from any cause |
| Secondary | Duration of response | 5.8 years | defined for patients with a best overall response of CR or PR determined by Lugano 2014 (PET-CT based response), defined as the time of 1st occurrence of CR or PR to disease progression/relapse or death from any cause |
| Secondary | Overall Response (OR) | End of treatment (12 months for experimental arm, 6 months for comparative arms) | assessed by investigator and IRC |
| Secondary | Duration of complete response | 4.6 years | for patients with a best overall response of CR determined by Lugano 2014 (PET-CT based response), define as the time of first occurrence of CR to disease progression/relapse or death from any cause |
| Secondary | Duration of complete response | 5.8 years | for patients with a best overall response of CR determined by Lugano 2014 (PET-CT based response), define as the time of first occurrence of CR to disease progression/relapse or death from any cause |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06284122/registered